FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileBlossomHill Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BLSM
BlossomHill Therapeutics, Inc. Stock AnalysisComprehensive stock analysis for BlossomHill Therapeutics, Inc. (BLSM) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisBLSM
BLSM
BlossomHill Therapeutics, Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
BLSM
  1. Home
  2. Stocks
  3. BlossomHill Therapeutics, Inc.
BL

BlossomHill Therapeutics, Inc.

🇺🇸BLSM•NASDAQ
BL

BlossomHill Therapeutics, Inc.

🇺🇸BLSM•NASDAQ
Market cap
$421.97M

Your view on BLSM

Mkt Cap
$421.97M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About BlossomHill Therapeutics, Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Jing Rong Jean Cui
Headquarters
10255 Science Center Drive, Suite 200, San Diego, CA, US
Industry
Biotechnology
Sector
Healthcare
CEO
Jing Rong Jean Cui
Headquarters
10255 Science Center Drive, Suite 200, San Diego, CA, US
Description

Blossomhill Therapeutics, Inc. is a biopharmaceutical company. It engages in the development of small molecule medicines for unmet medical needs in cancer treatment. The company was founded in June 2020 and is headquartered in San Diego, CA.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for BlossomHill Therapeutics, Inc.. Starting points for BlossomHill Therapeutics, Inc.: EPS -$2.53 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for BlossomHill Therapeutics, Inc.. Trailing twelve-month EPS for BlossomHill Therapeutics, Inc. stands at -$2.53. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Wall Street Analyst Estimates

Analysts' price targets, ratings, and revenue and EPS estimates.

Wall Street analysts· not FRC research
Nov 22, 2026
Analysts' target$38.33average of 3 firms, last 12 months
Current price—

Buy

Targets, low to high

$38.33

Low $35.00

Middle $40.00

High $40.00

Analyst ratings

2 ratings
  • Strong Buy0
  • Buy2
  • Hold0
  • Sell0
  • Strong Sell0
More →

Earnings per share estimates

Per shareThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate−$0.96−$0.88−$5.80−$3.38
Lowest estimate−$1.04−$0.93−$6.33−$3.77
Highest estimate−$0.87−$0.82−$5.27−$2.99
Number of analysts2123
A year ago————
Growth vs a year ago————

Revenue estimates

TotalThis quarterDec 2026Next quarterMar 2027This yearYear to Dec 2026Next yearYear to Dec 2027
Average estimate$0.00$0.00$0.00$0.00
Lowest estimate$0.00$0.00$0.00$0.00
Highest estimate$0.00$0.00$0.00$0.00
Number of analysts0000
A year ago————
Growth vs a year ago————
Recent rating and target changes (5)

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for BlossomHill Therapeutics, Inc.. BlossomHill Therapeutics, Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold BLSM20 companies · 8 funds
Compare BLSM with its peers, side by sidePremiumRatios, margins, valuation and leverage of the peers below — one table, one glance.Open Comparable Analysis
Peer companies
TickerTypeCompanySectorIndustryMkt cap
ACTUActuate Therapeutics IncHealthcareBiotechnology$5.4M
AGIOAgios Pharmaceuticals, Inc.HealthcareBiotechnology$1.7B
ALLRAllarity Therapeutics, Inc.HealthcareBiotechnology$12.6M
AVBPArriVent BioPharma, Inc. Common StockHealthcareBiotechnology$544.1M
FHTXFoghorn Therapeutics Inc.HealthcareBiotechnology$103.1M
FTHFaeth Therapeutics, Inc.HealthcareBiotechnology$203.1M
GLUEMonte Rosa Therapeutics, Inc.HealthcareBiotechnology$738.3M
NRIXNurix Therapeutics, Inc.HealthcareBiotechnology$1.4B
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
PTHSPelthos Therapeutics Inc.HealthcareAMEX$25.1M
PTIXProtagenic Therapeutics, Inc.HealthcareNASDAQ$470,654
PTNPalatin Technologies, Inc.HealthcareNASDAQ$8.2M
PTX.AXPrescient Therapeutics LimitedHealthcareASX—
PULMPulmatrix, Inc.HealthcareNASDAQ$4.6M
PVCTProvectus Biopharmaceuticals, Inc.HealthcareOTC$18.7M
PVLAPalvella Therapeutics, Inc.HealthcareNASDAQ$2.1B
PXMDPaxMedica, Inc. Common StockHealthcareOTC$37,879
PXXLFPoxel S.A.HealthcareOTC$13.4M
PYC.AXPYC Therapeutics LimitedHealthcareASX—
OBXObsidian Therapeutics Inc.HealthcareNASDAQ$12.5M
OCC.AXOrthocell LimitedHealthcareASX—
ETFs holding BlossomHill Therapeutics, Inc.
TickerFundFund assets% of the fund
VTIVanguard Total Stock Market ETF$689.2B in assets0.00%
VXFVanguard Extended Market ETF$30.2B in assets0.00%
VTWOVanguard Russell 2000 ETF$16.6B in assets0.00%
VUN.TOVanguard U.S. Total Market Index ETF$20.1B in assets0.00%
VTWGVanguard Russell 2000 Growth ETF$1.4B in assets0.00%
VEQT.TOVanguard All-Equity ETF Portfolio$17.6B in assets0.00%
VGRO.TOVanguard Growth ETF Portfolio$10.9B in assets0.00%
VTWVVanguard Russell 2000 Value ETF$1.3B in assets0.00%

Largest holders first, then the funds most concentrated in BLSM.

Open Comparable Analysis
Ownership & News

Insider Trading

Recent buying and selling by company executives.

About this section

Buying and selling by BlossomHill Therapeutics, Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for BlossomHill Therapeutics, Inc.. Coverage tracks BlossomHill Therapeutics, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of BlossomHill Therapeutics, Inc.

BLSM AnalysisFair
Past
1
Growth
2
Health
5
Profit
1
Value
1